We previously established an ovarian cancer targeted delivery system utilizing FP21 polypeptide as the targeting ligand, and the results indicated that further development and optimization of FSH-peptide-mediated PEI for targeted therapy of ovarian cancer was warranted. The gene discussed is BRD2; the disease is ovarian cancer.